| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1132: Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) |
|
Medicine details |
|
| Medicine name | ruxolitinib (Jakavi®) |
| Formulation | 5 mg, 10 mg, 15 mg and 20 mg tablet |
| Reference number | 9500 |
| Indication | Treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years |
| Company | Novartis Pharmaceuticals LTD |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/02/2026 |
| NICE guidance | |